CION Ameerpet
A brain MRI report can read like code. We translate every term — lesion, enhancement, oedema, impression — and show how it differs from your pathology report.
Being handed a brain MRI report can feel like reading a different language. Most of it is technical description meant for other doctors, not for you. The good news: once you know how a report is laid out, you can find the part that actually matters and ask the right questions.
This guide walks through a brain MRI report section by section, explains the words that worry people most, and shows how the MRI report is different from the pathology report that gives the final diagnosis. For the bigger picture of how brain tumours are diagnosed and treated, see the CION Brain Cancer & Tumour hub. Remember: an MRI describes how something looks — it cannot, on its own, confirm a tumour type or grade.
A brain MRI can suggest a tumour but cannot give the final diagnosis. The exact tumour type and grade come only from examining tissue under a microscope together with molecular tests. This is why the 2021 WHO Classification of Tumours of the Central Nervous System (WHO CNS5) — the standard followed worldwide and reflected in NCCN and EANO guidelines — defines brain tumours using both how the cells look and their molecular markers, not imaging alone.
Almost every MRI report follows the same structure. Knowing the order helps you skip to the part that answers your question. The single most important section is the impression — the radiologist's short summary at the end.
| Section | What it tells you |
|---|---|
| Clinical history | Why the scan was requested — for example a new headache, a seizure, or follow-up of a known lesion. |
| Technique | Which MRI sequences were run (such as T1, T2, FLAIR, diffusion) and whether contrast dye was given. |
| Comparison | Whether the scan was compared with earlier images — important for seeing if anything has changed. |
| Findings | The detailed description of what the radiologist saw — the size, location and features of any lesion, plus the rest of the brain. |
| Impression | The bottom-line summary. This is the part to read first — it states what the scan most likely shows and what the radiologist recommends next. |
Section names vary slightly between centres, but the order is consistent. If your report has a grade or diagnosis but no impression you understand, bring it to CION's brain tumour team in Hyderabad to talk it through.
These terms describe how a lesion looks. None of them, on its own, is a diagnosis — they are clues the radiologist weighs together.
A general word for any abnormal area seen on the scan. "Lesion" does not mean cancer — it simply flags something that is not normal brain tissue, which could be a tumour, a cyst, scar tissue, or other changes.
When part of a lesion lights up after the contrast dye (gadolinium) is given, it is called "enhancing". This happens where the brain's protective barrier is leaky. It is a useful clue but does not automatically mean malignancy — some benign tumours enhance brightly.
Swelling in the brain tissue around a lesion. It can cause symptoms by raising pressure. The amount of oedema is described because it affects both how you feel and how treatment is planned.
"Mass effect" means a lesion is pushing on nearby structures; "midline shift" means it is pushing the centre line of the brain across. These describe pressure, and may guide how urgently you are seen.
Different MRI "settings" that make tissues appear bright or dark in different ways. A lesion that is bright on one sequence and dark on another gives the radiologist clues about what it might be. You do not need to interpret these — they inform the impression.
Advanced sequences that measure blood flow and chemistry inside a lesion. They help judge how active a lesion may be, but — like everything on MRI — they suggest rather than confirm. A contrast MRI with these sequences gives the fullest picture before any biopsy.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
A scan or pathology report can feel frightening when no one explains it. Our neuro-oncology team reads it with you, line by line — across 35+ centres.
Patients often expect the MRI report to tell them their diagnosis. It cannot. The MRI shows the picture; the pathology report gives the verdict. Understanding the difference saves a lot of confusion and worry.
Written by a radiologist from your scan images. It describes a lesion's size, location, enhancement and surrounding changes, and gives a most-likely interpretation. It can say a lesion is "suspicious for a tumour" — but it cannot confirm the exact type or WHO grade.
Written by a pathologist who examines real tumour tissue under a microscope, with molecular tests. This gives the definitive diagnosis — the precise tumour type, the WHO grade, and markers such as IDH, 1p/19q and MGMT. It is the document that decides treatment.
So an MRI saying "likely glioma" is a strong lead, not a final answer. The tissue diagnosis confirms it — which is why most treatment plans wait for pathology.
From a worrying MRI to a confirmed diagnosis, the path usually has three steps. CION delivers the imaging, molecular testing and pathology coordination directly, and works with accredited neurosurgical partners for any tissue sampling.
The neuropathologist looks for specific features: how abnormal the cells appear, how fast they are dividing (mitotic activity), whether there is dead tissue (necrosis), and whether the tumour is forming new blood vessels. These, plus molecular markers, decide the grade.
Modern pathology reports for a malignant brain tumour include a molecular section. Since 2021, the WHO classifies brain tumours using these markers, not just how the cells look — two tumours that appear identical can be named and graded differently based on their genetics. CION arranges these tests as standard on every malignant glioma sample.
IDH (isocitrate dehydrogenase) status is the single most powerful marker in glioma. An IDH-mutated tumour generally behaves more favourably than an IDH wild-type tumour that looks the same under the microscope. Read more about what an IDH mutation means for a glioma.
The loss of parts of chromosomes 1p and 19q together defines an oligodendroglioma and is linked to better response to treatment — a defining feature in the current WHO system, not an optional extra.
In grade 4 glioblastoma, MGMT methylation status predicts how well the tumour is likely to respond to alkylating chemotherapy. It is essential for planning treatment and for discussing realistic expectations honestly.
If your pathology report has a grade but none of these markers, ask whether molecular testing was done. Book a free consultation or call 18002028726 to have your report and markers explained clearly.
The same MRI can look very different after treatment. After radiation and chemotherapy for a high-grade glioma, a follow-up scan can appear worse even when the tumour is responding — a phenomenon called pseudoprogression caused by inflammation, not tumour growth. EANO and NCCN guidance highlights this, which is why an experienced neuro-oncology team reads your surveillance MRIs in context rather than reacting to a single scan.
A scan or pathology report carries real weight, so it is reasonable — and often wise — to have it reviewed. For most brain tumours there is time to confirm the picture before treatment begins. A specialist review is especially valuable if:
CION offers a free written second opinion. Our tumour board can re-read the pathology, arrange any missing molecular tests, and explain — in plain language — what your reports truly mean. We follow NCCN and EANO guidelines, and every brain tumour case is reviewed by a multidisciplinary team so decisions are made for healing, not billing. Learn more on our brain tumour second-opinion & MRI review page, or request your free review now.
Get a free written second opinion from CION's tumour board — especially valuable if molecular testing such as IDH hasn't been done, or your reports seem unclear.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.A brain MRI report has a few key sections. The clinical history says why the scan was done. The technique lists the sequences used (such as T1, T2, FLAIR) and whether contrast was given. The findings describe what the radiologist saw — the size, location and features of any lesion. The impression (or conclusion) is the most important part: a short summary of what the scan most likely shows. Words like "mass", "lesion", "enhancement" or "oedema" describe appearances, not a final diagnosis. An MRI can suggest a tumour but cannot confirm the exact type or grade — only tissue under a microscope can. If anything is unclear, ask the team to walk you through the impression line by line, or bring it to a free second-opinion review.
During many brain MRIs, a contrast dye called gadolinium is given through a vein. It leaks into areas where the normal protective barrier of the brain (the blood–brain barrier) is disrupted — which can happen with some tumours, infections or inflammation. When part of a lesion lights up after contrast, the report calls it "enhancing". Enhancement is a useful clue, but it does not automatically mean cancer — some benign tumours enhance strongly, and some aggressive ones enhance little. The pattern of enhancement (uniform, ring-like or patchy) helps the radiologist judge how likely a lesion is to be a tumour, but only a biopsy gives a definite answer.
They answer different questions. The MRI report is written by a radiologist who describes what a lesion looks like on imaging — its size, location and behaviour with contrast. It can strongly suggest a tumour but cannot confirm the exact type or grade. The pathology report is written by a pathologist who examines actual tumour tissue from a biopsy or surgery under a microscope, together with molecular tests. This report gives the definitive diagnosis: the precise tumour type, the WHO grade, and markers such as IDH, 1p/19q and MGMT. In short — MRI shows the picture; pathology gives the verdict. You need both to build a complete treatment plan.
An MRI can give strong clues but cannot give a final answer. Features such as the lesion's shape, borders, contrast enhancement, surrounding swelling (oedema) and signal characteristics help the radiologist estimate whether a lesion is more likely benign or malignant. Advanced sequences — perfusion MRI and MR spectroscopy — add information about blood flow and chemistry inside the lesion. However, appearances overlap: some benign tumours look aggressive and some malignant ones look bland. Only a tissue biopsy with molecular testing can confirm whether a tumour is benign or malignant and give its exact WHO grade. Imaging guides the plan; pathology confirms it.
These are molecular markers tested on the tumour tissue. IDH (isocitrate dehydrogenase) status is the single most powerful marker in glioma — an IDH-mutated tumour generally behaves more favourably than an IDH wild-type tumour that looks the same under the microscope. 1p/19q co-deletion defines a tumour type called oligodendroglioma and is linked to better treatment response. MGMT methylation predicts how well a grade 4 glioblastoma may respond to alkylating chemotherapy. Under the 2021 WHO classification, these markers help decide the diagnosis and grade — not just the cells' appearance. If your pathology report has a grade but none of these markers, that is a good reason to ask whether molecular testing was done.
An incidental finding is something seen on a scan done for another reason; an indeterminate lesion is one the radiologist cannot fully characterise. Both are common and most turn out to be harmless. The usual next step is not panic but a plan: the team may recommend a short-interval follow-up MRI to see whether anything changes, referral to a neuro-oncology specialist, or in some cases further imaging. What matters is that the lesion is tracked, not ignored. Bring the report and the images (not just the typed report) to a specialist who can compare scans over time and advise whether monitoring or action is needed.
For a suspected or confirmed brain tumour, a specialist review is very reasonable — and for most patients there is time to do it before treatment begins. A neuro-oncology team can re-read the MRI images (not just the typed report), confirm the pathology, and check that molecular testing (IDH, 1p/19q, MGMT) has been done so the diagnosis meets current WHO criteria. CION offers a free written second opinion: bring your MRI images, the radiology report and any pathology and molecular results. Our tumour board reviews everything and explains, in plain language, what your reports mean and what the options are — a service detailed on our brain tumour second-opinion page.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.